SpyGlass Pharma, a clinical-stage biopharmaceutical company focused on chronic eye conditions, celebrated the grand opening of its new headquarters in Irvine, California on Thursday.

SpyGlass established its first laboratory space in Irvine in 2021, before expanding to a larger facility in Aliso Viejo and advancing its lead product candidate from the R&D phase to launch two Phase 3 clinical trials. The company outgrew its former facility following a successful IPO in February 2026, along with a strengthened leadership team and increased headcount. SpyGlass Pharma says that it looked to further expand its footprint as it plans to scale up for commercialisation of its innovative sustained drug delivery system and advance its ophthalmology pipeline.

Since completing its initial public offering in February 2026, which raised USD172.5m in gross proceeds, SpyGlass Pharma has grown its workforce by 33%, and now employs more than 85 people.

The new headquarters also provides expanded product development space as the company prepares for its next phase of growth.